Jacinda Abdul-Mutakabbor

Dr. Jacinda Abdul-Mutakabbor

Loma Linda University School of Pharmacy
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
LHLisa T Hong
Lisa T Hong
KDKevin J. Downes
Kevin J. Downes
AFAlireza FakhriRavari
Alireza FakhriRavari
Jacinda Abdul-MutakabborJacinda Abdul-Mutakabbor
Jacinda Abdul-Mutakabbor
JKJoseph L Kuti
Joseph L Kuti
MSMarc Scheetz
Marc Scheetz
Intravenous β‐lactam antibiotics remain a cornerstone in the management of bacterial infections due to their broad spectrum of activity and excellent tolerability. β‐lactams are well established to display time‐dependent bactericidal activity, where reductions in bacterial burden are directly associated with the time that free drug concentrations remain above the minimum inhibitory concentration (MIC) of the pathogen during the dosing interval. In an effort to take advantage of these bactericidal characteristics, prolonged (extended and continuous) infusions (PIs) can be applied during the administration of intravenous β‐lactams to increase time above the MIC. PI dosing regimens have been implemented worldwide, but implementation is inconsistent. We report consensus therapeutic recommendations for the use of PI β‐lactams developed by an expert international panel with representation from clinical pharmacy and medicine. This consensus guideline provides recommendations regarding pharmacokinetic and pharmacodynamic targets, therapeutic drug‐monitoring considerations, and the use of PI β‐lactam therapy in the following patient populations: severely ill and nonseverely ill adult patients, pediatric patients, and obese patients. These recommendations provide the first consensus guidance for the use of β‐lactam therapy administered as PIs and have been reviewed and endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of America (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists (SIDP).

12 August 2019 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
SJSarah C J Jorgensen
Sarah C J Jorgensen
EZEvan J Zasowski
Evan J Zasowski
TTTrang D Trinh
Trang D Trinh
ALAbdalhamid M Lagnf
Abdalhamid M Lagnf
SBSahil Bhatia
Sahil Bhatia
MRMichael J Rybak
Michael J Rybak
Background: Mounting evidence suggests the addition of a β-lactam (BL) to daptomycin (DAP) results in synergistic in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA) and bolsters the innate immune response to infection. This study’s objective was to provide clinical translation to these experimental data and determine if DAP+BL combination therapy results in improved clinical outcomes compared with treatment with DAP alone in patients with MRSA bloodstream infections (BSIs).Methods: This was a retrospective, comparative cohort study conducted at 2 academic medical centers between 2008 and 2018. Adults with MRSA BSI treated with DAP for ≥72 hours and initiated ≤5 days of culture collection were included. Patients who received a BL for ≥24 hours and initiated ≤24 hours of DAP comprised the DAP+BL group. The primary outcome was composite clinical failure (60-day all-cause mortality and/or 60-day recurrence). Analyses were adjusted for confounding using inverse probability of treatment weighting (IPTW).Results: A total of 229 patients were included (72 DAP+BL and 157 DAP). In unadjusted and IPTW-adjusted analyses, DAP+BL was associated with significantly reduced odds of clinical failure (odds ratio [OR], 0.362; 95% confidence interval [CI], .164–.801; adjusted OR, 0.386; 95% CI, .175–.853). Adjusted analyses restricted to prespecified subgroups based on infection complexity and baseline health status were consistent with the main analysis.Conclusions: The addition of a BL to DAP was associated with improved clinical outcomes in patients with MRSA BSI. This study provides support to ongoing and future studies evaluating the impact of combination therapy for invasive MRSA infections.Patients treated with daptomycin plus a β-lactam for MRSA bloodstream infection had lower odds of composite clinical failure defined as 60-day all-cause mortality and/or 60-day recurrence compared with patients treated with daptomycin monotherapy after adjusting for confounding variables using inverse probability of treatment weighting.

1 June 2021 in The Lancet Global Health
Verified
Journal Article
Open access
Jacinda Abdul-MutakabborJacinda Abdul-Mutakabbor
Jacinda Abdul-Mutakabbor
SCSamuel Casey
Samuel Casey
VJVeatrice Jews
Veatrice Jews
AKAndrea King
Andrea King
KSKelvin Simmons
Kelvin Simmons
JVJennifer Veltman
Jennifer Veltman

15 January 2020 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
SASara Alosaimy
Sara Alosaimy
Jacinda Abdul-MutakabborJacinda Abdul-Mutakabbor
Jacinda Abdul-Mutakabbor
RKRazie Kebriaei
Razie Kebriaei
SJSarah C. J. Jorgensen
Sarah C. J. Jorgensen
MRMichael J. Rybak
Michael J. Rybak

14 October 2021 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
Jacinda Abdul-MutakabborJacinda Abdul-Mutakabbor
Jacinda Abdul-Mutakabbor
NGNicole C. Griffith
Nicole C. Griffith
RSRyan K. Shields
Ryan K. Shields
FTFrank P. Tverdek
Frank P. Tverdek
ZEZahra Kassamali Escobar
Zahra Kassamali Escobar
The purpose of this narrative review is to bring together the most recent epidemiologic, preclinical, and clinical findings to offer our perspective on best practices for managing patients with A. baumannii infections with an emphasis on carbapenem-resistant A. baumannii (CRAB). To date, the preferred treatment for CRAB infections has not been defined. Traditional agents with retained in vitro activity (aminoglycosides, polymyxins, and tetracyclines) are limited by suboptimal pharmacokinetic characteristics, emergence of resistance, and/or toxicity. Recently developed and US Food and Drug Administration (FDA)-approved β-lactam/β-lactamase inhibitor agents do not provide enhanced activity against CRAB. On balance, cefiderocol and eravacycline demonstrate potent in vitro activity and are well tolerated, but clinical data for patients with CRAB infections do not yet support widespread use. Given that CRAB has the capacity to infect vulnerable patients and preferred regimens have not been identified, we advocate for combination therapy. Our preferred regimen for critically ill patients infected, or considered to be at high risk for CRAB, includes meropenem, polymyxin B, and ampicillin/sulbactam. Importantly, site of infection, severity of illness, and local epidemiology are essential factors to be considered in selecting combination therapies. Molecular mechanisms of resistance may unveil preferred combinations at individual centers; however, such data are often unavailable to treating clinicians and have not been linked to improved clinical outcomes. Combination strategies may also pose an increased risk for antibiotic toxicity and Clostridioides difficile infection, and should therefore be balanced by understanding patient goals of care and underlying health conditions. Promising therapies that are in clinical development and/or under investigation include durlobactam–sulbactam, cefiderocol combination regimens, and bacteriophage therapy, which may over time eliminate the need for the continued use of polymyxins. Future goals for CRAB management include pathogen-focused treatment paradigms that are based on molecular mechanisms of resistance, local susceptibility rates, and the availability of well-tolerated, effective treatment options.

23 June 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RKRazieh Kebriaei
Razieh Kebriaei
KLKatherine Lev
Katherine Lev
TMTaylor Morrisette
Taylor Morrisette
KSKyle C. Stamper
Kyle C. Stamper
Jacinda Abdul-MutakabborJacinda Abdul-Mutakabbor
Jacinda Abdul-Mutakabbor
MRMichael J. Rybak
Michael J. Rybak
Comparative time kill experiments with Staphylococcus aureus bacteriophage (phage) Sb-1 alone and phage-antibiotic combinations (PAC) against two methicillin-resistant S. aureus (MRSA) strains have shown synergy both with daptomycin-phage and vancomycin-phage combinations. PACs prevented development of phage resistance and demonstrated bactericidal activity for all triple combinations. In addition, the extracellular membrane vesicle (MV) formation and the potential impact of phage on MV suppression was examined. Our results demonstrate the potential of PAC for combating MRSA infections.